Clinical Acceptability Of Trimetazidine Modified-Release 80 mg Once Daily Versus Trimetazidine Modified-Release 35 mg Twice Daily In Stable Angina Pectoris
ConclusionsTMZ MR 80 mg od and TMZ MR 35 mg bid have similar safety profiles. This new once-daily formulation could improve patient compliance with therapy, thereby enhancing clinical benefit.Trial RegistrationISRCTN registry, ISRCTN 84362208.FundingInstitut de Recherches Internationales Servier and Servier, Moscow, Russian Federation.Plain Language SummaryPlain language summary available for this article.
Source: Cardiology and Therapy - Category: Cardiology Source Type: research
More News: Canada Health | Cardiology | Cardiovascular | Electrocardiogram | Heart | Laboratory Medicine | Russia Health | Study